Cholesterol Disorders

Your daily dose of clinical news you may have missed.

The analysis of a large biracial cohort found low levels of HDL-C linked to increased CHD risk in White but not Black adults and high HDL-C was not protective in either group.

Your daily dose of clinical news you may have missed.

The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.

In patients with hypertension, HDL-C >80 mg/dL was linked to a greater risk for CV events among men but not among women. Protective?

Less than 7% of the US population has "optimal" cardiometabolic health, with declines over 20 years significantly affecting racial/ethnic populations.

Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.

US CV health is well below ideal, with 80% of adults scoring as only low or moderate in the first published study using AHA's new Life's Essential 8 algorithm.

Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.

A new meta-analysis questions the science demonstrating the link between statin-induced LDL-C lowering and improved CV, all-cause outcomes.

AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.

AHA 2021: Study suggests remote hypertension and hyperlipidemia management programs may expand telehealth delivery, increase access to care, and reduce health inequities.

EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.

EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.

Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.

Assessment of CVD risk is the foundation of primary prevention and integral to primary care. Brush up on the fundamental tools of risk estimation from the ACC/AHA guidelines.

The FDA requests removal of pregnancy contraindication from statin prescribing information based on comprehensive reviews that found no evidence of an increase in birth defects.

In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.

Analysis of NHANES data shows significant downturns in control of the 3 risk factors in patients with diabetes, which could mean population-level increases in related illness.

ACC.21: High rates of obesity, hypertension, and hyperlipidemia found in Black women in their 20s and 30s are of significant concern, says the author of a study to be presented at the ACC meeting.

Robust analyses of urine metabolites detects poor adherence with prescribed treatment in T2D and is associated with prevalence of micro- and macrovascular complications.

Jackson Heart Study participants who maintained a healthy BP, BMI, and never smoked were at lower risk for incident CVD, suggesting targets for intervention in high-risk populations.

Heart disease, again the leading cause of death worldwide, may remain so for many years as a result of COVID-19 pandemic conditions, says AHA Update Writing Committee Chair.

Preview days 4 and 5 of the American Heart Association 2020 live late-breaking science sessions. Decide what you need to watch and when.

What to watch during the AHA 2020 late-breaking science sessions? We break down the first 3 days of clinical trial presentations for you, here.

Preventive Cardiology Collection Table of Contents: Expert video interviews, short, clinical guideline-focused quizzes, facts at-a-glance slideshows, plus news.

Cardiovascular medications are widely-prescribed in the US. Alex Evans, PharmD, MBA, drafted questions on the top 5 dangerous interactions he sees regularly in practice.